🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Overweight
Clinical trial register · Spain

Overweight Trials in Spain, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5885 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:52 UTC
5885
Studies in scope
all four open statuses
3103
Recruiting now
open to new participants
1139
Lead sponsors
across recruiting studies
Top sites
Seville 14 Barcelona 14 Madrid 12 Ferrol 8 Málaga 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company9 Novo Nordisk A/S6 Hoffmann-La Roche1 Amgen1 Karolinska Institutet1
Site location
Seville14 Barcelona14 Madrid12 Ferrol8 Málaga8
All 40 locations
Target enrolment
to

Overweight trials in Spain

22 of 5885 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
DrugOrforglipron
Eli Lilly and Company
Phase 3
2,001
Alcobendas, Barcelona, Centelles, Ferrol, Granada, Madrid, Pozuelo de Alarcón, Seville
2026-08-26
Recruiting
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841Overweight, Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 3
450
Fuenlabrada, Almería, Castilleja de la Cuesta, Ferrol, Madrid, Santiago de Compostela, Seville
2026-08-12
Recruiting
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Guadalajara, Pozuelo de Alarcón, Barcelona, Castilleja de la Cuesta, Lleida, Logroño, Madrid, Vitoria-Gasteiz
2026-05-05
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Guadalajara, Pozuelo de Alarcón, Barcelona, Castilleja de la Cuesta, Lleida, Logroño, Madrid, Vitoria-Gasteiz
2026-05-05
Recruiting
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307Obesity, Overweight, Osteoarthritis, Knee
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
400
A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela
2026-04-20
Active, closed
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
DrugBerobenatide
Pfizer
Phase 3
1,078
Málaga, Barcelona, Castilleja de la Cuesta, Chiclana de la Frontera, Madrid, Sanlúcar de Barrameda, Seville, Valencia
2026-02-24
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Guadalajara, Lleida, Logroño, Madrid, Málaga, Seville
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
A Coruña, Almería, Barcelona, Ferrol, Palma de Mallorca, Pozuelo de Alarcón, Santander, Seville
2026-02-10
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
460
Barcelona, Esplugues de Llobregat, Seville
2026-01-08
Recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity, Overweight
DrugRibupatide
Kailera
Phase 3
2,340
Ferrol, Seville, Villamartín, Barcelona, Oviedo, Castilleja de la Cuesta, Madrid, Valencia
2025-12-18
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Alzira, Barcelona, Madrid, Málaga, Santiago de Compostela, Seville
2025-12-15
Recruiting
Impact of Satiating Compounds and Hypocaloric Diet on Weight, Cardiometabolic and Osteoarticular Health in Obesity
NCT07165548Obesity, Overweight
Clinica Universidad de Navarra, Universidad de Navarra
Not applicable
144
Pamplona
2025-08-20
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
12,800
Castilleja de la Cuesta, Córdoba, Jaén, Málaga, Seville, San Cristóbal de La Laguna, Santander, Badalona
2025-07-25
Active, closed
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
465
Badajoz, Badalona, Barcelona, Madrid, Seville
2025-05-12
Active, closed
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413Obesity, Overweight, Overweight With One Weight Related Comorbidity
DrugsRO7204239·Tirzepatide
Hoffmann-La Roche
Phase 2
285
Seville, Santander, Castilleja de la Cuesta, A Coruña, Barcelona, Málaga
2025-05-05
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
905
A Coruña, Barcelona, Ferrol, Móstoles, Santander, Seville
2025-04-25
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
125
Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz
2024-11-18
Active, closed
OXXYNEA® GS: Study for Glycaemia Management
NCT05926947Prediabetic State, Overweight
Fytexia
Not applicable
87
Guadalupe
2023-07-05
By invitation
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
NCT05872022Pregnancy, Obesity, Overweight
Novo Nordisk A/S
Observational
728
Madrid
2023-07-05
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
3,127
A Coruña, Ferrol, Almería, Málaga, Seville, Badalona, Barcelona, Valladolid
2023-06-05
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
A Coruña, Almería, Alzira, Barcelona, Bilbao, Ferrol, Granada, León
2022-10-11
Active, closed
Overweight and Obesity in Preschoolers
NCT03800823Obesity, Overweight
Karolinska Institutet
Not applicable
300
Palma de Mallorca
2019-02-15
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-spain/condition/overweight

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,885 studies in total at the last sync on 26 Sep 2026, 19:52 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies listing the condition Overweight.

How many Overweight trials are recruiting in Spain?

13 of the 22 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:52 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Overweight), 22 studies
PhaseStudiesRecruitingShare
Phase 3171277.3%
Not applicable3113.6%
Observational104.5%
Phase 2104.5%

Most active sponsors

Lead sponsors with the most studies (Overweight)
Lead sponsorStudiesRecruiting
Eli Lilly and Company95
Novo Nordisk A/S65
Amgen11
Clinica Universidad de Navarra, Universidad de Navarra11
Fytexia10
Hoffmann-La Roche10
Kailera11
Karolinska Institutet10
Pfizer10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.